Effect of Alcohol on Obesity Related Liver Disease
Effect of Alcohol on Obesity Related Liver Disease
批准号:
8727960
负责人:
ARUN J SANYAL
金额:
$48.16万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-01 至 2016-07-31
关键词:
AdultAffectAlcohol consumptionAlcoholsAnimalsApoptosisArachidonate 15-LipoxygenaseArachidonate 5-LipoxygenaseAutomobile DrivingBiological MarkersBlood CirculationCaliforniaCirrhosisDataDevelopmentDietDiseaseEicosanoidsEnvironmentEnzymesEvaluationExposure toFatty LiverFatty acid glycerol estersFundingFutureGene Expression ProfileGeneticGoalsHepaticHistologyIn VitroIndividualInflammationInsulin ResistanceIntestinesKnowledgeLinkLipoxygenaseLiver diseasesMalignant neoplasm of liverMethodsMorbidity - disease rateMusNational Institute on Alcohol Abuse and AlcoholismObesityObesity associated liver diseaseOverweightOxidative StressPathogenesisPathway interactionsPermeabilityPhenotypePopulationPreventionPublic HealthReagentReportingResearch PersonnelRiskRoleRouteSeveritiesStagingStudy SubjectSystems BiologyTestingVascular DiseasesWorkalcohol effectalcohol researchcardiovascular disorder riskdrinking behaviorfeedinghigh riskhigh risk drinkingin vivoknock-downloss of functionmacrophagemicrobialmicrobiomemortalitymouse modelnon-alcoholic fatty livernovelpatient populationprograms
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Obesity- and alcohol-related diseases are two highly prevalent and important public health problems. Obese individuals who consume alcohol regularly are at high risk of developing fatty liver disease (FLD). Despite the commonality of obesity and alcohol consumption; the mechanisms by which varying amounts of alcohol consumption affect the development and severity of FLD in obese individuals remain poorly understood. The objective of this proposal is to elucidate the mechanisms by which varying amounts (0->60 gm/day) of alcohol consumption affect the development and progression of fatty liver disease in obese subjects. The central hypothesis to be tested is: In obese subjects, alcohol consumption alters the circulating profile of metabolites of intestinal microbial origin which activate circulating macrophages resulting in increased systemic activity of lipoxygenases (LOX) over and above that seen in obesity alone. LOX activation drives the severity of FLD by promoting insulin resistance, oxidative stress, inflammation and apoptosis. Two specific aims are proposed: (Aim 1) Define how alcohol increases the development and severity of FLD in obese subjects by (a) relating alcohol-induced changes in circulating gut microbiome-derived metabolites and eicosanoids to pathways driving fatty liver disease, and changes in intestinal permeability in obese subjects, (b) evaluation of the reversibility of alcohol-induced changes in the systemic profile of gut microbiome-derived metabolites and eicosanoids after successful completion of an alcohol cessation program, and (c) determining the effects of specific intestinal microbiome derived metabolites on LOX expression in vivo and in vitro in macrophages isolated from circulation and (Aim 2): To validate the relevance of LOX activity on the phenotype of FLD in two complementary mouse models of fatty liver disease that will be given isocaloric alcohol feeding via an intragastric route (Tsukamoto method). The animal alcohol feeding will be performed at the NIAAA-funded alcohol research center at the Univ. of Southern California. A systems biology approach will be taken to define the effects of alcohol consumption on systemic exposure to gut microbiome-derived metabolites, impact of such metabolites on LOX expression in circulating macrophages, impact of altered eicosanoid and intestinal microbiome-derived metabolite profile on the hepatic transcriptome and histology and the reversibility of these changes in those who cease to consume alcohol. The effects of specific microbial metabolites on LOX activity will be corroborated by directly testing their effects on specific LOX expression in macrophages isolated from circulation of the study subjects. The role of individual LOX will be determined by a loss of function approach using both pharmacologic and genetic methods to knock down the activity of 5-LOX and 12/15 LOX (aim 2). The investigators are uniquely suited to perform the proposed studies because of their expertise, environment and access to reagents. When these studies are completed, novel information on how alcohol intake modifies systemic LOX activity and the role of such changes in driving liver disease will be obtained.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Predicting outcomes in nonalcoholic steatohepatitis with advanced fibrosis
-
批准号:10446281
-
项目类别:
-
资助金额:$63.45万
-
财政年份:2022
-
负责人:ARUN J SANYAL
-
依托单位:
Predicting outcomes in nonalcoholic steatohepatitis with advanced fibrosis
-
批准号:10696227
-
项目类别:
-
资助金额:$58.05万
-
财政年份:2022
-
负责人:ARUN J SANYAL
-
依托单位:
A PRECLINICAL MODEL OF ALCOHOLIC HEPATITIS
-
批准号:10213324
-
项目类别:
-
资助金额:$37.65万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
Novel Therapies for Alcoholic Hepatitis with Sepsis and for Relapse Prevention
-
批准号:10428495
-
项目类别:
-
资助金额:$6.31万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
Novel Therapies for Alcoholic Hepatitis with Sepsis and for Relapse Prevention
-
批准号:10190742
-
项目类别:
-
资助金额:$6.31万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
A PRECLINICAL MODEL OF ALCOHOLIC HEPATITIS
-
批准号:9792231
-
项目类别:
-
资助金额:$19.34万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 9/9
-
批准号:10202389
-
项目类别:
-
资助金额:$36.34万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 9/9
-
批准号:10887713
-
项目类别:
-
资助金额:$11.67万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
Novel Therapies for Alcoholic Hepatitis with Sepsis and for Relapse Prevention
-
批准号:9791143
-
项目类别:
-
资助金额:$7.44万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
A PRECLINICAL MODEL OF ALCOHOLIC HEPATITIS
-
批准号:10459568
-
项目类别:
-
资助金额:$33.13万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 9/9
-
批准号:9752430
-
项目类别:
-
资助金额:$36.34万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 9/9
-
批准号:10441262
-
项目类别:
-
资助金额:$35.25万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
A PRECLINICAL MODEL OF ALCOHOLIC HEPATITIS
-
批准号:10245322
-
项目类别:
-
资助金额:$38.12万
-
财政年份:2018
-
负责人:ARUN J SANYAL
-
依托单位:
TREAT-VCU
-
批准号:8546294
-
项目类别:
-
资助金额:$43.53万
-
财政年份:2012
-
负责人:ARUN J SANYAL
-
依托单位:
TREAT-VCU
-
批准号:8890718
-
项目类别:
-
资助金额:$49.78万
-
财政年份:2012
-
负责人:ARUN J SANYAL
-
依托单位:
TREAT-VCU
-
批准号:8428385
-
项目类别:
-
资助金额:$35.36万
-
财政年份:2012
-
负责人:ARUN J SANYAL
-
依托单位:
TREAT-VCU
-
批准号:8727961
-
项目类别:
-
资助金额:$50.49万
-
财政年份:2012
-
负责人:ARUN J SANYAL
-
依托单位:
Effect of Alcohol on Obesity Related Liver Disease
-
批准号:8323527
-
项目类别:
-
资助金额:$50.1万
-
财政年份:2011
-
负责人:ARUN J SANYAL
-
依托单位:
Effect of Alcohol on Obesity Related Liver Disease
-
批准号:8508767
-
项目类别:
-
资助金额:$46.38万
-
财政年份:2011
-
负责人:ARUN J SANYAL
-
依托单位:
Effect of Alcohol on Obesity Related Liver Disease
-
批准号:8204326
-
项目类别:
-
资助金额:$50.33万
-
财政年份:2011
-
负责人:ARUN J SANYAL
-
依托单位:
海外基金